Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:
“Dato-DXd may be redefining frontline TNBC for patients ineligible for immunotherapy.
TROPION-Breast02 now shows benefit extending beyond initial progression:
- PFS2
- Time to first subsequent therapy
- Time to second subsequent therapy
Key results from Abstract 1002:
TROPION-Breast02
- Previously untreated unresectable/metastatic TNBC
- ICI not an option
- N = 644
Arms: Dato-DXd vs Investigator’s choice chemotherapy
Key efficacy:
- OS: HR 0.79
- PFS: HR 0.57
New secondary endpoint data:
- PFS2:
- 15.6 vs 11.8 mo
- HR 0.61
TFST: 10.9 vs 5.6 mo HR 0.49
TSST: 16.7 vs 12.6 mo HR 0.67
Responses were >2× higher with Dato-DXd in prior analysis, with longer duration of response and manageable toxicity.
The signal here is important: This is not just delaying first progression. Dato-DXd appears to delay the need for next-line therapy and preserve downstream disease control.
ADC era in TNBC keeps accelerating. ”
Title: First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.
Authors: David W. Cescon, Tiffany A. Traina, Peter Schmid, Javier Cortes, Zhimin Shao, Shigehira Saji, Kyung Hae Jung, Thomas Bachelot, Shouman Wang, Emilio M. Ramírez, Gul Basaran, Yee Soo Chae, Agostina Stradella, Rofhiwa Mathiba, Shin-Cheh Chen, Nicola Battelli, Naoki Niikura, Kechen Zhao, Micah J. Maxwell, Rebecca A. Dent
Read the Full Abstract.
Other articles featuring Rishabh Jain on OncoDaily.